Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Skin Cancer

Skin Cancer

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Skin Cancer

59 trials tracked for Skin Cancer: 2 in phase 3 or 4.

59Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 31 Phase 1 5 Other / NA 21
  1. Phase 4 Topical Antibiotic Prophylaxis for Eyelids Completed
  2. Phase 3 An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma Completed
  3. Phase 2 Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors Completed
  4. Phase 2 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed
  5. Phase 2 Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer Completed
  6. Phase 2 Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection Completed
Show 44 more trials
  1. Phase 2 Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin Completed
  2. Phase 2 Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy Completed
  3. Phase 2 Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma Completed
  4. Phase 2 Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma Completed
  5. Phase 2 Photodynamic Therapy in Treating Patients With Skin Cancer Completed
  6. Phase 2 Study of ADI-PEG 20 in Patients With Advanced Melanoma Completed
  7. Phase 2 A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma Completed
  8. Phase 2 sEphB4-HSA in Treating Patients With Kaposi Sarcoma Completed
  9. Phase 2 Study of TVEC in Patients With Cutaneous Squamous Cell Cancer Completed
  10. Phase 2 Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma Completed
  11. Phase 2 Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... Completed
  12. Phase 2 Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas Completed
  13. Phase 2 Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Completed
  14. Phase 2 Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma Completed
  15. Phase 2 Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer Completed
  16. Phase 2 Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Completed
  17. Phase 2 Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma Completed
  18. Phase 2 Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes Completed
  19. Phase 2 Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... Completed
  20. Phase 2 Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma Completed
  21. Phase 2 Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma Completed
  22. Phase 2 Preventing Squamous Cell Skin Cancer Completed
  23. Phase 2 Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma Completed
  24. Phase 2 Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma Completed
  25. Phase 2 Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection Completed
  26. Phase 2 Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back Completed
  27. Phase 2 Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer Completed
  28. Phase 1 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Completed
  29. Phase 1 Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) Completed
  30. Phase 1 Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use Completed
  31. Phase 1 Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma Completed
  32. Phase 1 Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen Completed
  33. N/A Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer Completed
  34. N/A RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction Completed
  35. N/A Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment Completed
  36. N/A Social Media Indoor Tanning Study Completed
  37. N/A Post Excision/Mohs Scar Laser Resurfacing Completed
  38. N/A Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery Completed
  39. N/A An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk Completed
  40. N/A Strategies to Promote Skin Health Completed
  41. N/A Virtual Sun Safe Workplaces Ph II (SSW Works) Completed
  42. N/A Microwave Therapy for Treatment of Precancerous Actinic Keratoses Completed
  43. N/A Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin Completed
  44. N/A The Impact of Total Body Skin Examination on Skin Cancer Detection Completed

Showing the 50 most-cited and recently-updated of 59 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Skin Cancer: what the trials found

Pembrolizumab has been evaluated in clinical trials for skin cancer, with data showing that 100% of participants experienced adverse events during the study period 17. Additionally, Pembrolizumab was assessed in a separate trial involving a small cohort 10.

The use of a topical antibiotic product demonstrated a statistically significant reduction in the number of participants with surgical site infections (0 vs 5; p=0.025) compared to a control group. No significant differences were observed regarding wound dehiscence (p=0.77) or allergic contact dermatitis (p=1.00) 4.

BMS-986205 was evaluated in a Phase 3 trial for this condition 5.

Recent results — preliminary, needs further review

  • Recombinant EphB4-HSA Fusion Protein was evaluated in a Phase 2 study 1.
  • Pomalidomide was assessed in a Phase 2 trial, where the incidence of Grade 3 or higher toxicities was reported at 57.7% and 38.5% respectively 2.
  • SSW Works showed varying results for percentage change from baseline employee sunburn prevalence at 1 year (90%, 91%, 35%, and 23%) 3.
  • Aldesleukin was evaluated in a Phase 2 trial, where clinical response rates (objective tumor regression) varied across groups (27.5%, 27.1%, 19.6%, 37.5%, 0%, and 0%) 6.

For the clinician treating this condition

  • Pembrolizumab is established in clinical literature for skin cancer, though it is associated with a 100% incidence of adverse events in reported cohorts.
  • A topical antibiotic product significantly reduces the risk of surgical site infections compared to standard care.
  • Recent trials are investigating various novel agents including Recombinant EphB4-HSA Fusion Protein and Pomalidomide, though large-scale outcomes for these specific interventions remain pending.

AI synthesis of 8 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
CDKN3 expression varies across cancer types and lacks a universal role in tumor progression
Dermatology Sys. Review
CDKN3 expression varies across cancer types and lacks a universal role in tumor progression Exploring the Role of CDKN3 Protein in Various Types of Cancer
This narrative review examines the role of CDKN3 across various malignancies, including lung, renal, and hepatocellular cancers. The authors…
Scientists are looking at how the CDKN3 protein affects different cancers, including lung, skin, and breast cancer, to find better treatment…
Frontiers Oct 31, 2026
AI decision support in nurse-led teledermoscopy associated with 1.73 odds ratio for malignancy detection
Dermatology RCT
AI decision support in nurse-led teledermoscopy associated with 1.73 odds ratio for malignancy detection AI tools help nurses identify more skin cancer cases
This multi-site observational study evaluated 1,102,382 lesions from 98,422 patients in a teledermoscopy framework. AI decision support was …
Artificial intelligence helped nurses identify more skin cancer cases and provide more frequent treatment recommendations during skin screen…
medRxiv Oct 3, 2026